SOPH vs TEM: fair value comparison
SOPHiA GENETICS SA and Tempus AI, Inc. · Updated 2026-10-19
SOPH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. TEM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SOPH currently ranks higher by quality score.
| SOPH | TEM | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $6.73 | $64.72 |
| 12-month range | $3.89–$8.92 | $41.55–$91.58 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #160 of 301 Healthcare | #161 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | High |
| Margin trend | Contracting | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: SOPH fair value analysis · TEM fair value analysis